A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients

Cancer
I I RaadG P Bodey

Abstract

The improved efficacy of imipenem over other beta-lactam antibiotics in the treatment of febrile neutropenic patients has been attributed to its broad spectrum of activity. A prospective, randomized, clinical trial was performed comparing vancomycin 1 g every 12 hours plus imipenem/cilassatin 500 mg every 6 hours and the same dose of vancomycin plus aztreonam 2 g every 6 hours for empiric treatment of febrile episodes in neutropenic patients with cancer. The imipenem regimen cured 76% of the 148 evaluable episodes compared with a 67% cure rate for the 152 episodes treated with the aztreonam regimen (p = 0.1). Most of the polymicrobial infections (77% or 10/13) treated with the imipenem responded, whereas only 38% (5/13) of these infections responded to the aztreonam regimen. Although the cost of the imipenem regimen was less than the cost of the aztreonam regimen, it was associated significantly more with skin rashes (12/194 vs 3/189, p = 0.02). In a multivariate analysis, a poor outcome was independently associated in both instances with the persistence of neutropenia and the presence of pneumonia (p < 0.001). Overall, in a multifactorial analysis that included efficacy, toxicity, and cost, the imipenem and aztreonam regimens ...Continue Reading

References

May 1, 1978·The American Journal of the Medical Sciences·D G Maki, A A Schuna
Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W T HughesL S Young
Jun 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L S EltingB H Keefe
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·UNKNOWN EORTC International Antimicrobial Therapy Cooperative Group
Mar 23, 1990·The American Journal of Medicine·H C Neu
Jul 1, 1990·Antimicrobial Agents and Chemotherapy·R LiangD Todd
Jan 1, 1990·Pediatric Hematology and Oncology·C HauerH Lackner
Nov 1, 1988·The Journal of Antimicrobial Chemotherapy·R LiangD Todd
Apr 1, 1988·The Journal of Antimicrobial Chemotherapy·C ViscoliF Meunier
Aug 1, 1986·The American Journal of Medicine·P G JonesG P Bodey
Aug 1, 1986·Antimicrobial Agents and Chemotherapy·G P BodeyV Fainstein
Jul 1, 1986·Medicine·L S EltingV Fainstein
Nov 1, 1985·Reviews of Infectious Diseases·S C Schimpff
May 13, 1971·The New England Journal of Medicine·S SchimpffA Serpick
Mar 1, 1983·Reviews of Infectious Diseases·R BolivarG P Bodey
Jan 1, 1983·Archives of Internal Medicine·D J WinstonW J Martin
Feb 1, 1995·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·UNKNOWN Hospital Infection Control Practices Advisory Committee (HICPAC)
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A G FreifeldR C Young
May 6, 1993·The New England Journal of Medicine·P A Pizzo

❮ Previous
Next ❯

Citations

Feb 19, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Walter T HughesLowell S Young
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
Nov 6, 2008·Critical Care : the Official Journal of the Critical Care Forum·Thomas G Slama
Dec 14, 2007·Expert Opinion on Pharmacotherapy·David P Nicolau
May 27, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Georg MaschmeyerGloria Mattiuzzi
Apr 30, 1999·Mayo Clinic Proceedings·W C Hellinger, N S Brewer
Oct 21, 1998·Infectious Disease Clinics of North America·B A Collin, R Ramphal
Oct 15, 2013·Transplant Infectious Disease : an Official Journal of the Transplantation Society·B J McCulloughJ R Wingard
Jun 1, 2000·Infectious Disease Clinics of North America·L E Asbel, M E Levison
Aug 28, 2010·BMC Pulmonary Medicine·Marya D ZilberbergAndrew F Shorr
May 25, 2016·International Journal of Antimicrobial Agents·Konstantinos Z VardakasMatthew E Falagas
Jun 6, 2007·Expert Review of Anti-infective Therapy·Mickael Aoun
Feb 2, 2000·Bone Marrow Transplantation·C A MullenK W Chan
Mar 15, 2006·Annals of Hematology·Stefan Neuburger, Georg Maschmeyer
May 13, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·N Le GuyaderG Leverger
Nov 12, 2010·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L S EltingG Bodey
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FeldW Ho
May 17, 2000·Seminars in Roentgenology·J M Aronchick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.